Thursday Jun 13
A randomized phase II study to evaluate tacrolimus in combination...
To insert individual citation into a bibliography in a word-processor, select your preferred citation style below and drag-and-drop it into the document.
Wed Jun 12, 2013
Micell Technologies Receives CE Mark Approval for MiStent SES
The MiStent SES is unique in providing local drug delivery both during and after the period of polymer absorption, thereby eliminating long-term polymer exposure, a potential cause of delayed healing and late adverse events.
Mon Jun 10, 2013
Epstein-Barr virus-associated smooth muscle tumors after kidney...
BACKGROUND: Epstein-Barr virus-associated smooth muscle tumors in adult kidney transplant recipients are rare.
Fri Jun 07, 2013
Thu Jun 06, 2013
Sunlight linked to drug's effectiveness
ISLAMABAD: A new study has demonstrated that the body's ability to break down medicines may be closely related to exposure to sunlight, and thus may vary with the seasons.
Mon May 27, 2013
OrbusNeich Launches World's First Dual Therapy Stent That...
The introduction of the COMBO Stent is in conjunction with the company's receipt of a CE Mark for the product and involves a sales roll-out in The COMBO Dual Therapy Stent is the first stent to both accelerate endothelial coverage and control neo-intimal proliferation through the combination of OrbusNeich's proven pro-healing technology with an ... (more)
Fri May 24, 2013
Medical News Today
Bioresorbable Drug-Eluting Scaffolds Emerging As The Dominant...
Main Category: Heart Disease Also Included In: Cardiovascular / Cardiology ; Medical Devices / Diagnostics Article Date: 24 May 2013 - 1:00 PDT The DESolve bioresorbable coronary scaffold system achieves good efficacy and safety with low rates of late lumen loss and major coronary adverse events at six months, show first results from the pivotal ... (more)
Results Of The BIOFLOW-II Substudy: Biodegradable Stent Proves Non-Inferior To Drug-Eluting Stent
The Orsiro stent, which is a novel stent platform eluting sirolimus from a biodegradable polymer, demonstrated non-inferiority to the Xience Prime everolimus-eluting stent for the primary angiographic endpoint of in-stent late lumen loss at nine months in the results of an imaging substudy reported at EuroPCR 2013 today.
Thu May 23, 2013
Customer Interaction Solutions
Svelte Drug-Eluting Stent Utilizing New Class of Bioabsorbable Drug...
Final 6 and 12-month results of the DIRECT first-in-man clinical study were presented by study principal investigator Dr.
Tue May 21, 2013
Biodegradable stent proves non-inferior to drug-eluting stent
The BIOFLOW-II substudy used intravascular ultrasound and optical coherence tomography to quantitatively assess neointimal hyperplasia and stent apposition at nine months after treating patients with symptomatic coronary artery disease due to de novo stenotic lesions.